


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound represented by Formula (I):



wherein:

R^1 is selected from the group consisting of hydrogen, halo, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C1-C6) haloalkyl, hydroxy, (C1-C6) alkoxy, amino, (C1-C6) alkylamino, amide, sulfonamide, cyano, substituted or unsubstituted (C6-C10) aryl;

R^2 is selected from the group consisting of hydrogen, halo, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C1-C6) haloalkyl, hydroxy, (C1-C6) alkoxy, (C2-C8) alkoxyalkyl, amino, (C1-C6) alkylamino, (C6-C10) arylamino;

R^3 is selected from the group consisting of hydrogen, (C1-C6) alkyl, (C6-C10) aryl, (C5-C10) heteroaryl, and amide;

R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen and (C1-C6) alkyl;

each R^7 is independently selected from the group consisting of hydrogen, (C1-C6) alkyl and hydroxyl;


R^8 is selected from the group consisting of hydroxy, (C1-C6) O-alkyl, (C3-C8) O-cycloalkyl, and NR^9R^{10} ; where R^9 and R^{10} are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) hydroalkyl, (C1-C6) dihydroxyalkyl, (C1-C6) alkoxy, (C1-C6) alkyl carboxylic acid, (C1-C6) alkyl phosphoric acid, (C1-C6) alkyl sulfuric acid, (C1-C6) hydroxyalkyl carboxylic acid, (C1-C6) alkyl amide, (C3-C8) cycloalkyl, (C5-C8) heterocycloalkyl, (C6-C8) aryl,

(C5-C8) heteroaryl, (C3-C8) cycloalkyl carboxylic acid, or R^9 and R^{10} together with N forms a (C5-C8) heterocyclic ring either unsubstituted or substituted with one or more hydroxyls, ketones, ethers, and carboxylic acids; and

n and m are independently 0, 1, 2, or 3; p is 1, 2, or 3;


or, a pharmaceutically acceptable salt, its tautomer, a pharmaceutically acceptable salt of its tautomer, or a prodrug thereof.

Claim 2 (original): The compound, salt, tautomer, or prodrug according to claim 1 selected from the group represented by the following structures:




wherein R^2 is selected from the group consisting of hydrogen and fluoro.

Claim 3 (original): The compound, salt, tautomer, or prodrug according to claim 1 represented by the following structure:



Claim 4 (original): The compound, salt, tautomer, or prodrug according to claim 1 represented by Formula (II):



wherein R^{8a} is selected from the group consisting of hydrogen, (C1-C6) alkyl, and (C3-C8) cycloalkyl.

Claim 5 (original): The compound, salt, tautomer, or prodrug according to claim 4, wherein:


R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro;

R^3 and R^4 are methyl;


R^5 , R^6 , R^7 and R^{8a} are hydrogen; and

n and m are independently 0, 1, or 2.


Claim 6 (original): The compound, salt, tautomer, or prodrug according to claim 5 selected from the group consisting of:



Claim 7 (original): The compound, salt, tautomer, or prodrug according to claim 5 represented by the following structure:




Claim 8 (original): The compound, salt, tautomer, or prodrug according to claim 5 represented by the following structure:



Claim 9 (original): A compound, salt, tautomer, or prodrug according to claim 1 represented by Formula (III):

- 5 -



wherein R^{8a} is selected from the group consisting of hydrogen, (C1-C6) alkyl, and (C3-C8) cycloalkyl.

Claim 10 (original): The compound, salt, tautomer, or prodrug according to claim 9, wherein:


R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro;

R^3 and R^4 are methyl;

R^5 , R^6 , and R^{8a} are hydrogen; and


n and p are independently 1, or 2.

Claim 11 (original): The compound, salt, tautomer, or prodrug according to claim 10 selected from the group consisting of:




Claim 12 (original): The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:


- 6 -




Claim 13 (original): The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:



Claim 14 (original): The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:



Claim 15 (original): A compound, salt, tautomer, or prodrug according to claim 9 represented by Formula (IIIa):



Formula IIIa

wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro;


R^3 and R^4 are methyl;

R^5 , R^6 , and R^{8a} are hydrogen; and

n and p are 2.

- 7 -

Claim 16 (original): A compound, salt, tautomer, or prodrug according to claim 15 represented by Formula (IIIb):




wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro; and

R^3 and R^4 are methyl.

Claim 17 (original): A compound, salt, tautomer, or prodrug according to claim 1 represented by Formula (IV):



wherein R^8 is NR^9R^{10} .

Claim 18 (original): The compound, salt, tautomer, or prodrug of claim 17, wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen, halo, cyano;

R^3 , R^4 , R^5 and R^6 are independently hydrogen or (C1-C6) alkyl;

R^7 is hydrogen, or hydroxyl;


n , and p are independently 1, or 2;

m is 0 or 1; and


- 8 -

R^9 and R^{10} are selected from the group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) dihydroxyalkyl, (C1-C6) alkoxy, (C1-C6) alkyl carboxylic acid, (C1-C6) alkyl phosphoric acid, (C1-C6) alkyl sulfuric acid, (C1-C6) hydroxyalkyl carboxylic acid, (C1-C6) alkyl amide, (C3-C8) cycloalkyl, (C5-C8) heterocycloalkyl, (C6-C8) aryl, (C5-C8) heteroaryl, (C3-C8) cycloalkyl carboxylic acid, or R^9 and R^{10} together with N forms a (C5-C8) heterocyclic ring either unsubstituted or substituted with one or more hydroxyls, ketones, ethers, and carboxylic acids.


Claim19 (original): The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




Claim 20 (original): The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:



Claim 21 (original): The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




Claim 22 (original): The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




- 10 -

Claim 23 (original): The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




Claim 24 (original): The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




wherein n is 0, 1, or 2.

Claim 25 (original): The compound, salt, tautomer, or prodrug according to claim 24 selected from the group represented by the following structures:


- 11 -




Claim 26 (original): The compound, salt, tautomer, or prodrug according to claim 24 selected from the group represented by the following structures:



Claim 27 (original): The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




Claim 28 (original): The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:



Claim 29 (original): The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:

- 13 -




wherein:

R² is selected from the group consisting of hydrogen and fluoro; and

R⁸ is selected from the group consisting of radicals represented by the following structures:

- 14 -



Claim 30 (canceled)

Claim 31 (currently amended): A method for the modulation of the catalytic activity of a protein kinase with a compound or salt of any one of claims 1-~~30~~ 29.

Claim 32 (original): The method of claim 31, wherein said protein kinase is selected from the group consisting of VEGF receptors and PDGF receptors.